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ABSTRACT
Background: In phase 3 trials, the once-daily
human glucagon-like peptide-1 analog
liraglutide provided effective glycemic control
with low rates of hypoglycemia, weight loss,
and reduced systolic blood pressure (SBP) in
patients with type 2 diabetes. Through a
retrospective clinical audit, the authors aimed
to assess the clinical effectiveness of liraglutide,
from initiation to first hospital visit, when
prescribed at a center in Northern Ireland.
Methods: Patients attending Ulster Hospital
who were prescribed liraglutide (June 2009–
September 2010) and assessed both at baseline
and first post-initiation visit were included in
the analysis. The primary endpoint was change
in glycated hemoglobin (HbA1c) from baseline.
Weight, blood pressure, and frequency of
hypoglycemic events were also assessed.
Results: Data from 193 patients are reported
(baseline HbA1c 9.0%, mean age 55.8 years,
diabetes duration 8.8 years, 66.8% male).
Average time to first visit after initiation was
13.5 weeks, at which point 174 patients (90.2%)
were prescribed 1.2 mg liraglutide. Mean
change in HbA1c from initiation to first visit
was -0.9%, while mean body weight change
was -2.4 kg and change in SBP was
-2.0 mmHg. Transient gastrointestinal side
effects were experienced by 11.9% of patients.
The number of patients experiencing minor
hypoglycemic events was low (5.7%) and no
major events were reported.
Conclusion: Data from clinical studies translate
into clinical practice: liraglutide provided
improved glycemic control after 13.5 weeks of
treatment, accompanied by weight loss and low
incidence of hypoglycemia.
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INTRODUCTION
In clinical trials of patients with type 2 diabetes,
glucagon-like peptide-1 (GLP-1) receptor
agonists have been shown to provide effective
glycemic control when used in combination
with oral antidiabetic drugs (OADs) [1].
However, data regarding the use of GLP-1
receptor agonists in clinical practice are scarce.
Here, the authors report data from the use of the
once-daily human GLP-1 analog liraglutide in
clinical practice.
Liraglutide is a once-daily human GLP-1
analog with 97% amino acid sequence
identity to native GLP-1 [2]. In phase 3
trials, liraglutide has been found to provide
glycemic control alongside potential
beneficial effects on body weight, reductions
in systolic blood pressure (SBP), and
improved beta-cell function [3–9].
Liraglutide treatment has also been found
to be associated with a low risk of
hypoglycemia, particularly when used
without concomitant sulfonylurea treatment
[3–9]. Liraglutide 1.2 mg is recommended by
the UK National Institute for Health and
Clinical Excellence (NICE) for use in
certain patients as second-line therapy
(in combination with metformin or
sulfonylurea) or third-line therapy (in
combination with metformin ? sulfonylurea,
or metformin ? thiazolidinedione) [10].
The authors aimed to assess the clinical
effectiveness of liraglutide, from treatment
initiation to first hospital visit, when
prescribed at a center in Northern Ireland.
The authors hypothesized that in a real-life
clinical setting, despite the use of different
background therapies, liraglutide treatment
would result in comparable changes in HbA1c,
body weight, and SBP to those observed in
clinical trials.
MATERIALS AND METHODS
The authors assessed all patients who were
prescribed liraglutide at Ulster Hospital from
June 2009 to September 2010 and present
data showing changes from baseline to the
first hospital visit after initiation of
liraglutide. In line with recommendations
for initiating liraglutide and improving
gastrointestinal (GI) tolerability, the starting
dose of liraglutide was 0.6 mg daily. After
1 week, the dose was increased to 1.2 mg once
daily. The primary endpoint assessed was
change in glycated hemoglobin (HbA1c) from
baseline to first clinic visit after the initiation
of liraglutide. Data on body weight, SBP,
hypoglycemia, and GI side effects were also
assessed. Error is standard deviation (SD)
unless otherwise stated. Stata 10 (StataCorp,
2007) was used to calculate means (SD) by
summary descriptive statistics after data
manipulation [11]. No statistical tests were
performed.
RESULTS
Patient Demographics and Baseline
Characteristics
A total of 193 patients were included in the
audit, 50 of whom (25.9%) were prescribed
liraglutide off-license with existing insulin
regimens (off-license use of liraglutide was
initiated on investigator request and it was
their sole responsibility). Among patients
taking insulin in combination with liraglutide,
13 used basal insulin at baseline, 27 used basal–
bolus regimens, and 10 used a premixed insulin.
A total of 129 (66.8%) patients were male. The
mean (SD) patient age was 55.8 (9.7) years, and
mean (SD) duration of diabetes was 8.8 (5.4)
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years. Mean (SD) HbA1c was 9.0 (1.5)%, SBP
133.5 (16.3) mmHg, and diastolic blood
pressure 75.2 (9.5) mmHg. Mean (SD)
cholesterol levels were 3.98 (0.89) mmol/L,
low-density lipoprotein cholesterol 1.89
(0.76) mmol/L, high-density lipoprotein
cholesterol 1.06 (0.25) mmol/L, and
triglyceride levels were 2.46 (1.5) mmol/L. In
line with recommendations [10], liraglutide was
initially prescribed at a dose of 0.6 mg to
improve GI tolerability and the dose could be
escalated to 1.2 mg after 1 week of treatment.
The average time from treatment initiation to
first post-initiation visit was 13.5 weeks. At the
time of the first post-initiation visit, 174
(90.2%) patients were prescribed liraglutide
1.2 mg and 19 (9.8%) were receiving
liraglutide 0.6 mg. No patients were prescribed
liraglutide 1.8 mg at the first post-initiation
visit.
Efficacy
From baseline, mean (SD) HbA1c in the overall
patient group (n = 193) reduced by 0.9 (1.1)%,
from 9.0 (1.5)% to 8.1 (1.4)% (75 and
65 mmol/mol, respectively; Table 1). Mean
(SD) body weight decreased by 2.4 (7.3) kg
from a baseline of 116.7 (24.0) kg to 114.4
(22.8) kg at the first post-initiation visit. In
addition, mean (SD) SBP was reduced by 2.0
(±17.1) mmHg from a baseline of 133.5
(±16.3) mmHg to 131.0 (±16.2) mmHg at the
first post-initiation visit. For patients using
insulin (n = 50), the average insulin dose
remained stable: mean basal doses were 70.6
and 70.0 U, and bolus doses were 79.4 and
76.3 U, at baseline and first visit, respectively.
The insulin-treated group had a mean (SD)
baseline HbA1c of 9.2 (±1.3)% (77 mmol/mol)
and a 0.8 (±1.1)% reduction was observed at
the first post-initiation visit.
Tolerability
Twenty-three (11.9%) patients experienced GI
effects, a known side effect of liraglutide, and
these were mainly transient. Eleven (5.7%)
patients experienced minor hypoglycemia,
nine (81.8%) of these were taking concomitant
sulfonylureas and one (0.09%) was taking basal
insulin.
DISCUSSION
The changes observed here are comparable to
those in phase 3 trials of liraglutide 1.2 mg in
combination with OADs, in which HbA1c
decreases ranged from 1.0 to 1.5%, weight
change from ?0.3 to -2.9 kg, and SBP
decreases from 0.6 to 6.7 mmHg following
26-week treatment [3, 4, 6, 9]. At 5.7%, the
occurrence of minor hypoglycemia in this study
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also reflects data from phase 3 trials of patients
using liraglutide 1.2 mg in combination with
OADs [3, 4, 6, 9]. Limitations of the present
study include its single-arm observational
design, the absence of a fixed timeline for the
first visit, and the fact that it was conducted at a
single center. Furthermore, patients received
concomitant medications that may have
affected the measured outcomes, and these
medications may have changed during the
course of the study.
In this study, the insulin dose did not need
to be reduced in patients who were using
liraglutide with insulin. This observation is
likely to be a reflection of the fact that initial
glycemic control in these patients was poor. A
clinical trial of the GLP-1 receptor agonist
exenatide twice daily in combination with
insulin also showed reductions in HbA1c [12],
and another trial exploring the sequential
addition to metformin of liraglutide and then
insulin detemir also reported good glycemic
control, sustained weight loss, and low rates of
hypoglycemia [13]. Based on these data, in
Europe, exenatide twice daily is licensed for
use in combination with basal insulin, and
insulin detemir can be added to existing
liraglutide therapy [14, 15]. It should be
remembered that the addition of liraglutide to
basal insulin is off-license, but if the
combination is prescribed, the insulin dose
should be monitored to minimize
hypoglycemia; in the trial combining
exenatide with insulin, patients with
HbA1c B8.0% (64 mmol/mol) had their insulin
dose reduced by 20% during the addition of
exenatide treatment [10].
In conclusion, the data reported here show
that results from clinical trials of liraglutide
translate into real-life clinical practice.
Liraglutide was well tolerated with a low
incidence of hypoglycemia. Liraglutide
improved glycemic control, body weight, and
SBP, indicating that liraglutide is effective in a
real-life setting.
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